Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03640208|
Recruitment Status : Recruiting
First Posted : August 21, 2018
Last Update Posted : March 19, 2021
The burden of colorectal cancer (CRC) is unequal among various populations within the United States. This inequality is most notable among African Americans, who exhibit the highest CRC mortality of all US populations. This study aims to evaluate a community-based intervention to educate, assess risk, and overcome barriers to screening among African Americans who are 45 years or older with no personal history of CRC, adenomas, or inflammatory bowel disease and have no family history of CRC.
Barriers being assessed include: Need for establishing care with primary care physician, need for financial assistance, need for reminder calls, need for transportation, need for appointment coordination, and need for education about colonoscopy preparation and procedure
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Behavioral: Education presented by trained caregiver||Not Applicable|
After reviewing the existing literature this study team believes that the proposed strategy is inherently unique, thus amenable to experimental inquiry.
The study will provide much needed data to define the extent to which the proposed multi-faceted approach may be effectively deployed to the target population. This includes the acquisition of data to evaluate the educational program, for which improvement in knowledge may be tested objectively using the study design, as well as survey and feasibility data which is pivotal for improving the strategy.
The 11 steps for completing cancer screening are listed below:
- Demographic/Socio-economic information
- Knowledge assessment and education
- Risk assessment questionnaire "Am I Average Risk?"
- Do I need screening colonoscopy?
- Barriers to colorectal cancer screening
- Outreach program evaluation
- Participants data entered in REDCap database
- Communication with primary care provider and navigator
- Participant navigation
- Evaluation of navigation services
- Program monitoring
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluating the Effectiveness of A Proposed 11-Step Community-Based Interventional Program That Educates, Assesses Risk And Overcomes Barriers to Complete Screening Colonoscopy Among Average Risk African Americans|
|Actual Study Start Date :||February 27, 2019|
|Estimated Primary Completion Date :||September 2021|
|Estimated Study Completion Date :||September 2021|
Experimental: Complete colorectal screening
11 step process divided into three phases: 1. Community Outreach Event; 2. Data Collection; 3. Navigation and Program Monitoring
Behavioral: Education presented by trained caregiver
After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
- Difference in paired pre-/post-test score [ Time Frame: From baseline (week 0) to follow-up end of study (week 24) ]16 item knowledge questions, where each item is assessed as true, false, or not sure. A 25% improvement of knowledge between pre- and post-test scores will indicate an effective program
- Acceptability of intervention [ Time Frame: At the end of education - 24 weeks ]Metrics (convenient, appropriate, effective, satisfaction) will be measured on a 5-point scale where the two most favorable categories (i.e. strongly agree and agree) will be considered a positive response.
- Feasibility of Intervention [ Time Frame: At the end of education - 24 weeks ]
Measured by evaluating practicality or logistics of the proposed interventional program with 8 item dichotomous questionnaire.
A 100% positive response on the questionnaire (all 8 items answered 'yes') will be considered a 'positive' questionnaire for an individual participant. If 80% of participants respond with an overall 'positive' questionnaire, the study will be considered feasible.
- Fidelity of intervention [ Time Frame: At the end of education - 24 weeks ]
Number of documented deviations throughout the program.
90% of the 11-step program needs to be followed. A 'deviation' would be defined as not adhering to one of the 11 steps.
- Percentage of individuals aged 45-75 who have never had colon or rectal cancer screening [ Time Frame: At the end of education - 24 weeks ]Percentage of individuals aged 45-75 who have never had colon or rectal cancer screening
- Percentage of participants who found the Risk assessment questionnaire helpful [ Time Frame: At the end of education - 24 weeks ]Metrics will be measured on a 5-point scale where the two most favorable categories (i.e. strongly agree and agree) will be considered a positive response.
- Barriers faced to scheduling colorectal cancer screening [ Time Frame: At the end of education - 24 weeks ]Percent of participants with barriers to receiving colorectal cancer screening.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03640208
|Contact: Samir Abraksia, MD||1-866-223-8100||TaussigResearch@ccf.org|
|United States, Ohio|
|Cleveland Clinic, Case Comprehensive Cancer Center||Recruiting|
|Cleveland, Ohio, United States, 44122|
|Contact: Samir Abraksia, MD 866-223-8100 TaussigResearch@ccf.org|
|Principal Investigator: Samir Abraksia, MD|
|Principal Investigator:||Samir Abraksia, MD||Cleveland Clinic, Case Comprehensive Cancer Center|